Éxito de la ortopedia prequirúrgica en pacientes con labio fisurado y paladar hendido ­ Revisión de alcance / Sucesso pré-cirúrgico em ortopedia em pacientes com fissura de labio e palato - Revisão da abordagem / Pre-surgical orthopedics success in patients with cleft lip and cleft palate - Scoping review

Resumen: Kerr McNeil, protesista escocés introdujo la ortopedia maxilar neonatal hace más de dos siglos, fue así que sugirió inicialmente que la reposición de los segmentos maxilares mediante aparatos ortopédicos producía una maxila aparentemente normal. Se han descrito distintos tipos de aparatología ortopédica prequirúgica, divididos en tres categorías: activos, semiactivos y pasivos. Objetivo: Realizar una búsqueda de la literatura en bases de datos indexadas sobre el éxito de la ortopedia prequirúrgica en pacientes con labio fisurado y paladar hendido. Metodología: Se realizó una búsqueda computarizada en las siguientes bases de datos electrónicas: PUBMED, SCIENCEDIRECT, PROQUEST, COCHRANE, OVIDSP SCOPUS, Y MEDLINE. Los buscadores booleanos utilizados en las diferentes bases de datos fueron OR, AND, NOT. Resultados: Trece artículos cumplieron con los criterios de elegibilidad y se incluyeron en esta revisión, 4 son estudios observacionales descriptivos longitudinales y prospectivos, 5 son reportes de casos clínicos, 1 es en estudio retrospectivo, 1 es una revisión Cochrane, 2 son casos y controles; el uso de la ortopedia dependía del caso de extensión y severidad según la fisura labiopalatina y el tiempo de uso debía ser desde el momento del nacimiento del bebé hasta los 3 meses de vida. Conclusión:La ortopedia prequirúrgica es exitosa si se usa desde el momento del nacimiento y hasta los tres meses de vida, ofreciendo resultados satisfactorios y de manera eficaz disminuyendo la hendidura palatina, la deformidad nasal y la fisura labial antes de practicar la queilorrafia y la palatorrafia.

Resumo: Kerr McNeil, um protesista escocês introduziu a ortopedia maxilar neonatal há dois séculos, estabelecendo o conceito de uso de peças ortopédicas para produzir uma maxila mais natural. Três tipos diferentes de ortopedia pré-cirúrgica foram descritos. São eles: ativo, semi-ativo e passivo. Objetivo: Realizar uma pesquisa em dados indexados sobre o sucesso do tratamento ortopédico pré-cirúrgico em pacientes com quadro de fissura labiopalatina. Metodologia: Foi realizada pesquisa informatizada em bancos de dados eletrônicos como: PUBMED, SCIENCEDIRECT, PROQUEST, COCHRANE, OVIDSP SCOPUS e MEDLINE. As pesquisas booleanas utilizadas nas bases de dados múltiplas foram OR, AND, NOT. Resultados: Treze artigos atenderam aos padrões de elegibilidade e foram incluídos nesta revisão. 4 (quatro) deles são estudos observacionais descritivos, longitudinais e prospectivos. 5 (cinco) são relatórios clínicos, 1 (um) é um estudo retrospectivo, 1 (um) é uma revisão Cochrane e 2 (dois) são casos clínicos e check ups. A implantação do tratamento ortopédico dependeu do tipo de extensão dos casos e da gravidade da fenda palatina. Conclusão: a ortopedia pré-cirúrgica tem sucesso se implementada ao nascimento até os 3 meses de idade. Assegura resultados satisfatórios diminuindo consideravelmente a fenda palatina, a malformação nasal e a fenda labial antes da realização dos procedimentos de Queilorrafia e Palatorrafia

Kerr McNeil, Scottish prosthetic introduced the Neonatal maxillary orthopedics two centuries ago setting the concept of using orthopedic parts to. Three different types of pre-surgical orthopedics have been described. These are: active, semi-active and passive. Objective: Perform a research in indexed data regarding the success of pre-surgical orthopedics treatment in patients with a condition of cleft lip and cleft palate. Methodology: A computer based research was performed at electronic data bases such as: PUBMED, SCIENCEDIRECT, PROQUEST, COCHRANE, OVIDSP SCOPUS, and MEDLINE. The Booleans researches used in the multiples data bases were OR, AND, NOT. Findings: Thirteen papers met the eligibility standards and were included in this review. 4 (four) of them are descriptive, longitudinal and prospective observational studies. 5 (five) are clinic reports, 1 (one) is a retrospective study, 1 (one) is a Cochrane review, and 2 (two) are clinic cases and check ups. The orthopedics treatment implementation depended on the kind of extension cases and severity of the cleft palate. Conclusion: the pre-surgical orthopedics is successful if it is implemented at birth up to 3 months of age. It assures satisfactory results decreasing considerably cleft palate, nasal malformation, and cleft lip before performing Cheilorrhaphy and Palatorrhaphy procedures. Key words: Cleft lip, cleft palate, orthopedic surgery, palatal obturators, nose deformities

[Prevalence and features of chronic pain among patients with schizophrenia]. / Estudio transversal de prevalencia y características del dolor crónico en pacientes con esquizofrenia.

BACKGROUND: People with schizophrenia generally refrain from manifesting somatic symptoms, and may not complain of pain. Therefore these patients may have an insensitivity to pain. AIM: To determine the prevalence of chronic pain in a sample of patients with schizophrenia. PATIENTS AND METHODS: The McGill Pain Questionnaire (MPQ) was answered by 79 outpatients with schizophrenia with a mean age of 47 years (67% men) attended at a public hospital in Chile. RESULTS: Chronic pain, defined as lasting more than six months, was reported by 15.2 % of patients. Acute pain was reported by 63% of patients. No significant differences were observed in sociodemographic characteristics or duration of illness between patients with acute or chronic pain. The assessment of the different pain dimensions showed a predominance of sensory and affective components, with pain rating indexes of 0.82 and 0.71, respectively. CONCLUSIONS: These results indicate that the prevalence of pain among people with schizophrenia, is similar to that of the general population.

How to interpret diagnostic tests. / Cómo interpretar las pruebas diagnósticas.

Healthcare professionals make decisions in a context of uncertainty. When making a diagnosis, relevant patient characteristics are categorized to fit a particular condition that explains what the patient is experiencing. During the diagnostic process, tools such as the medical interview, physical examination, and other complementary tests support this categorization. These tools, known as diagnostic tests, allow professionals to estimate the probability of the presence or absence of the suspected medical condition. The usefulness of diagnostic tests varies for each clinical condition, and studies of accuracy (sensitivity and specificity) and diagnostic impact (impact on health outcomes) are used to evaluate them. In this article, the general theoretical and practical concepts about diagnostic tests in human beings are addressed, considering their historical background, their relationship with probability theories, and their practical utility with illustrative examples.

En el ámbito de la salud, los profesionales deben tomar decisiones en un marco de incertidumbre. Al realizar un diagnóstico, se categorizan los signos y síntomas, sumados a los hallazgos de exámenes complementarios de una condición clínica particular, implicando la definición de un tratamiento y pronóstico específico. Durante el proceso diagnóstico se utilizan herramientas de la anamnesis, examen físico y exámenes complementarios para apoyar dicha categorización. Estas herramientas, conocidas como pruebas diagnósticas, permiten estimar la probabilidad de la presencia o ausencia de la condición médica sospechada. La utilidad de las pruebas diagnósticas varía para cada condición clínica y se evalúan mediante estudios de exactitud (sensibilidad y especificidad) e impacto diagnóstico (repercusión sobre los desenlaces de salud). En este artículo, se abordan los conceptos teóricos y prácticos generales sobre las pruebas diagnósticas en seres humanos considerando sus antecedentes históricos, su relación con las teorías sobre probabilidades y su utilidad práctica con ejemplos ilustrativos.

Estudio transversal de prevalencia y características del dolor crónico en pacientes con esquizofrenia / Prevalence and features of chronic pain among patients with schizophrenia

Background: People with schizophrenia generally refrain from manifesting somatic symptoms, and may not complain of pain. Therefore these patients may have an insensitivity to pain. Aim: To determine the prevalence of chronic pain in a sample of patients with schizophrenia. Patients and Methods: The McGill Pain Questionnaire (MPQ) was answered by 79 outpatients with schizophrenia with a mean age of 47 years (67% men) attended at a public hospital in Chile. Results: Chronic pain, defined as lasting more than six months, was reported by 15.2 % of patients. Acute pain was reported by 63% of patients. No significant differences were observed in sociodemographic characteristics or duration of illness between patients with acute or chronic pain. The assessment of the different pain dimensions showed a predominance of sensory and affective components, with pain rating indexes of 0.82 and 0.71, respectively. Conclusions: These results indicate that the prevalence of pain among people with schizophrenia, is similar to that of the general population.

Angiotensin-converting-enzyme inhibitors and angiotensin II receptor blockers for COVID-19: A living systematic review of randomized clinical trials.

OBJECTIVE: This living systematic review aims to provide a timely, rigorous, and continuously updated summary of the evidence available on the role of angiotensin-converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB) in the treatment of patients with COVID-19. DATA SOURCES: We conducted searches in PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), grey literature and in a centralized repository in L·OVE (Living OVerview of Evidence), which retrieves articles from multiple sources such as PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, among other pre-print and protocols repositories. In response to the COVID-19 emergency, L·OVE (Living OVerview of Evidence) was adapted to expand the range of evidence and customized to group all COVID-19 evidence in one place on a daily search basis. The search covered a period of time up to July 31, 2020. ELIGIBILITY CRITERIA FOR SELECTING STUDIES AND METHODS: We adapted an already published standard protocol for multiple parallel living systematic reviews to this question's specificities. We included randomized trials evaluating the effect of either suspension or indication of angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers as monotherapy, or in combination versus placebo or no treatment in patients with COVID-19. We searched for randomized trials evaluating the effect of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers versus placebo or no treatment in patients with COVID-19. Two reviewers independently screened each study for eligibility, extracted data, and assessed the risk of bias. We pooled the results using meta-analysis and applied the GRADE system to assess the certainty of the evidence for each outcome. We will resubmit results every time the conclusions change or whenever there are substantial updates. RESULTS: We screened 772 records, but none was considered for eligibility. We identified 55 ongoing studies, including 41 randomized trials evaluating angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for patients with COVID-19. CONCLUSIONS: We did not find a randomized clinical trial meeting our inclusion criteria, and hence there is no evidence for supporting the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in the treatment of patients with COVID-19. A substantial number of ongoing studies would provide valuable evidence to inform researchers and decision-makers in the near future. PROSPERO REGISTRATION NUMBER: CRD42020182495. PROTOCOL PREPRINT DOI: 10.31219/osf.io/vp9nj.

OBJETIVO: Esta revisión sistemática viva tiene como objetivo proporcionar un resumen oportuno, riguroso y continuamente actualizado de la evidencia disponible sobre el rol de los inhibidores de la enzima convertidora de angiotensina (iECA) y los bloqueadores del receptor de angiotensina II (ARA-II) en el tratamiento de pacientes con COVID-19. FUENTES DE DATOS: Realizamos búsquedas en PubMed/Medline, Embase, Cochrane Central Register of Controlled Trials (CENTRAL), literatura gris y en el repositorio centralizado L·OVE (Living OVerview of Evidence) que recupera artículos de múltiples fuentes como PubMed/MEDLINE, Cochrane Central Register of Controlled Trials, Embase, entre otros repositorios de preprints y protocolos. En respuesta a la emergencia de COVID-19, L·OVE (Living OVerview of Evidence) se adaptó para ampliar el rango de información que cubre y se personalizó para agrupar toda la evidencia en torno a COVID-19 en un solo lugar, en una base de búsqueda diaria. La búsqueda cubrió el período hasta el 31 de julio de 2020. CRITERIOS DE ELEGIBILIDAD PARA LA SELECCIÓN DE ESTUDIOS Y MÉTODOS: Adaptamos un protocolo común ya publicado para múltiples revisiones sistemáticas vivas paralelas a las especificidades de esta pregunta. Se incluyeron ensayos aleatorizados que evaluaban el efecto de la suspensión o la indicación de inhibidores de la enzima convertidora de angiotensina o bloqueadores de los receptores de angiotensina II, como monoterapia o en combinación, versus placebo o ningún tratamiento, en pacientes con COVID-19. Se buscaron ensayos aleatorizados que evaluaran el efecto de los inhibidores de la enzima convertidora de angiotensina/bloqueadores del receptor de angiotensina II versus placebo o ningún tratamiento en pacientes con COVID-19. Dos revisores examinaron de forma independiente la elegibilidad de cada estudio, extrajeron los datos y evaluaron el riesgo de sesgo. Los resultados se agruparon mediante un metanálisis y se aplicó GRADE para evaluar la certeza de la evidencia para cada resultado. Cada vez que cambien las conclusiones o hayan actualizaciones sustanciales, volveremos a enviar un reporte. RESULTADOS: Analizamos 772 artículos, pero ninguno cumplió con los criterios de inclusión. Identificamos 55 estudios en curso, incluidos 41 ensayos aleatorizados que evaluaban inhibidores de la enzima convertidora de angiotensina/bloqueadores del receptor de angiotensina II para pacientes con COVID-19. CONCLUSIONES: No encontramos ningún ensayo clínico aleatorizado que cumpliera con nuestros criterios de inclusión y, por lo tanto, no hay pruebas que respalden el papel de los inhibidores de la enzima convertidora de angiotensina y los bloqueadores de los receptores de angiotensina II en el tratamiento de pacientes con COVID-19. Identificamos un número considerable de estudios en curso que podría proporcionar evidencia valiosa para informar a los investigadores y a los responsables de la toma de decisiones en un futuro próximo.